In conclusion, our in‐depth study revealed that BCL2 activated IRF4 by enhancing its nuclear activity to induce SOX9 aberrant expression, which is a critical pathway for drug resistance in BCL2‐overexpressing DLBCL. The gene discussed is SOX9; the disease is diffuse large B-cell lymphoma.